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Abstract Premature ejaculation is the most frequent male
sexual dysfunction, significantly impairing quality of life of
both the patient and the partner and affecting up to one-
third of men of every age. In the last years, our knowledge
about this topic has greatly increased, and studies on the
causes and treatments related to ejaculatory disorders have
shed a light on previously uncharted territory. Public
interest on sexual dysfunctions has likewise increased in
the general population: the time lapse between the first
symptoms of sexual dysfunction and the seeking of medi-
cal advice has been significantly reduced, whereas demand
for a treatment has markedly increased. A role of endocrine
regulation has been established in all the aspects of male
reproduction; however, the endocrine control of ejaculation
is not fully understood. Sex steroid, pituitary, and thyroid
hormones have all been advocated as potential candidates
in the regulation of the ejaculatory process, but exact
mechanisms are not clear yet and further studies are
required in order to identify potential targets for treatment.
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Introduction
Although consistent information about its prevalence is
lacking [1], premature ejaculation (PE) is the most frequent
male sexual disorder [2]: according to different criteria, its
prevalence might widely vary, ranging from 8 to 30 % [3]
up to 22–38 % [4] in all age groups, yet very few men seek
treatment. PE is ‘‘a culture-dependent symptom that is self-
identified, self-reported, and self-rated’’. For this reason, a
conclusive definition is hard to reach: many authors and
several scientific societies have provided different defini-
tions of PE [5], classifying PE on time of onset, patho-
genesis, and situational occurrence. Nonetheless, three
common constructs underlie most definitions of PE: (1)
brief ejaculatory latency; (2) loss of control; and (3) psy-
chological distress in the patient and/or partner.
The Diagnostic and Statistical Manual of Mental Dis-
orders, Fifth Edition (DSM-5) definition of PE includes the
approximately 1-minute intravaginal ejaculatory latency
time (IELT) criteria as well as the inclusion of distress. It
also asks the clinician to specify the subtypes of lifelong
and acquired, generalized, or situational dysfunction as
well as its severity. Anteportal ejaculation is the term
applied to men who ejaculate prior to vaginal penetration
and is considered the most severe form of PE [6].
In 1917, PE was considered a symptom of neurosis,
requiring psychoanalysis; in later years a more ‘‘psycho-
biological’’ view was hypothesized and PE was considered
a psychosomatic disorder [7]. In the seventies, Masters and
Johnson postulated that PE occurred as the result of a
learned behavior; this definition was considered the most
up to date until the end of the century, when Waldinger
identified genetic and neurobiological determinants of PE
[8, 9]. A ‘‘Manichean’’ distinction between psychogenic
and organic pathogenesis of PE is under close scrutiny, and
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represents one of the most frequent controversies in sexual
medicine [10, 11]: neurotransmitters are involved as much
as psychological issues [12], partially explaining the dif-
ferences between lifelong and acquired forms of PE.
However, it is important to consider the fundamental role
of the partner in determining the development of PE. In fact,
PE is maybe the only partner-oriented male sexual symp-
tom, since the ejaculatory precocity refers to partner sexual
physiology and to the time course of the female sexual
response [13]. Hence, the PE lives only inside of the couple.
In the field of male sexual dysfunctions, PE and erectile
dysfunction (ED) are frequently coexistent in the same
subject [14, 15]: based on their role on erectile function and
sexual drive, hormones have been recently investigated in
order to assess the exact endocrine mechanisms pertaining
to ejaculation.
Androgens play a pivotal role in preserving sexual
health [16, 17], but many other hormones are somehow
involved in erectile function [18, 19]: even if more recent
papers have provided a better insight on the endocrine
control of the ejaculatory reflex [20, 21], existing guide-
lines on premature ejaculation provide little information on
this matter [22–25]. The aim of this review is to provide a
quick, easy-to-read reference which might be useful to the
physician during clinical practice.
Testosterone
The role of testosterone in maintaining male sexual health
has been elucidated in many papers, though its association
with PE is still unclear [26]. It has been proven that testos-
terone affects the ejaculatory process [27], improving the
control of ejaculation. In humans, testosterone acts on a
peripheral level by regulating the expression and activity of
nitric oxide (NO) synthase and type 5 phosphodiesterase
(PDE5); It is known that high levels of intrapenile nitric
oxide act as a local neurotransmitter to facilitate the relaxa-
tion of intracavernosal trabeculae, thereby maximizing blood
flow and penile engorgement. In addition, the NO-PDE5
system also affects the ejaculation process by regulating the
contractility of the male genital tract [28, 29]. As a result, a
low testosterone level may reduce the volume of ejaculate in
hypogonadal patients [30] leading to a delayed ejaculation.
Clinical studies have confirmed those pathophysiological
aspects of testosterone showing that hypogonadal men are
usually prone to develop delayed ejaculation, whereas higher
levels of testosterone are often correlated to PE.
In animal models, testosterone has proven to be able to
exert its effects on different levels: at hypothalamic level,
higher levels of testosterone are able to suppress serotonin,
leading to a development of PE [31], whereas at spinal
level testosterone regulates nuclei involved in the control
of ejaculation. These findings, however, have yet to be
confirmed in humans.
In addition, the literature evidence regarding the
gonadotropins role related to PE is still severely lacking. A
recent research found no significant correlation between
luteinizing hormone (LH) and PE, although patients with
PE had significantly higher levels of follicle stimulating
hormone (FSH) [32]; these results, however, disagree with
previous findings on the same topic [26].
Estrogens
Antagonism between testosterone and estradiol is often
suggested as a possible cause of ED [33–35]. Estrogens are
classically involved in female sexual excitation, but their
receptors (ER-a and ER-b) have been discovered in the
epididymis of rabbits and other animal species [36]. Some
authors have hypothesized that estrogens are also involved
in epididymal contractility in humans and are designated to
achieve fertility [37]. Furthermore, estrogens are funda-
mental for activities involving the sympathetic activity of
smooth muscle cells [38], including sexual stimulation.
Oxytocin
Oxytocin is an oligopeptide synthesized in the paraven-
tricular and supraoptic hypothalamic nuclei and secreted by
the posterior pituitary gland and it is mostly known for its
role in stimulating lactation; however, its role in males has
not been fully investigated. Research on this topic has
shown that oxytocin is a potent inducer of penile erection
in rodents [39]; based on these findings, more recent
studies have shown that oxytocin levels in human plasma
greatly increase during orgasm [40]. In rats, oxytocin
showed a facilitatory effect on ejaculation by reducing the
ejaculatory latency time and post-coital refractory time
[41]; on the other hand, rodents with lower oxytocin levels
had longer mount and refractory time, providing further
demonstration of a role of this hormone on ejaculation
[42]. However, administration of exogenous oxytocin has
not shown the expected results: in a small group of healthy
men, intranasal application of oxytocin did not have any
significant effect on sexual behavior [43]. On the other
hand, oxytocin receptors blockade via highly selective
antagonists has shown promising effects in treating PE
[44]. Oxytocin facilitates male and female reproductive
behavior [45]: increased central and peripheral oxytocin
levels perhaps might provide an answer to the role of the
serotoninergic system in facilitating erection, ejaculation,
and penile detumescence [46]. There are still a few missing
pieces from this puzzle but we can assume that research on
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oxytocin and its relation to ejaculation disorders is far from
being complete.
Prolactin
In female mammalians, prolactin (PRL) is involved in
lactation; however, in males elevated PRL levels inhibit
pulsatile secretion of gonadotropin-releasing hormone
(GnRH), leading to a form of secondary hypogonadism.
High PRL levels might impair sexual function in otherwise
healthy men: this rarely happens in mild hyperprolactine-
mia ([20 ng/ml) but becomes a more common finding in
severe hyperprolactinemia ([35 ng/ml). Elevated PRL is
most commonly associated with delayed ejaculation,
whereas lower PRL has been observed more consistently in
patients suffering from PE; these findings have been con-
firmed even after adjusting for age, body mass index,
medicaments, and smoking habit. Low PRL levels have
also been observed in patients with high anxiety and
guiltiness during masturbation, suggesting perturbations of
the neurological pathway involving serotonin and its
receptors. In a consecutive series of 2,531 outpatients
consulting for sexual dysfunctions, PRL in the lowest
quartile levels is associated with Metabolic Syndrome and
ED, as well as with PE and anxiety symptoms [47].
However, in a recent study [32], no significant difference
was found between PRL levels of subjects with PE and
healthy men: it seems that there is still a lot to be dis-
covered regarding the role of PRL in ejaculation disorders.
Thyroid hormones
The effect of thyroid hormones on human behavior has
been thoroughly investigated. Receptors for thyroid hor-
mones have been found in the male genital tract [48]: based
on this assumption, a role of thyroid hormones in PE has
been postulated [49]. Hyperthyroidism in animal models
has been advocated as a possible cause, or even a risk
factor, of premature ejaculation [50, 51]: even if the first
studies in men did not lead to certain results [52], a role of
thyroid hormones has been already confirmed in humans
[53]. Treatment of hyperthyroidism has proven to be
effective for PE: after normalizing thyroid function in
hyperthyroid men, the prevalence of PE fell from 50 to
15 % [49]. A role for hyperthyroidism-induced anxiety in
causing PE was also investigated [54, 55]. However, at
multivariate analysis, even after adjusting for anxiety, a
low TSH was independently predictive of PE [54]. It was
also shown the medical treatment of the opposite state,
hypothyroidism, resulted in a twofold decrease in ejacu-
latory latency [47]. Hence, both hyper- and hypothyroidism
have been advocated as causes of sexual health disorders
[56]: diagnosing and treating thyroid disorders might have
lead to a significant improvement in quality of life. How-
ever, the assessment should be made only after performing
careful medical history and physical examination, in order
to evaluate the most common features and symptoms of
hypo- or hyperthyroidism.
Adrenal hormones
To date, literature is severely lacking regarding the role of
adrenal hormones in PE. Among adrenal androgens,
androstenedione, DHEA, and DHEAS are undoubtedly the
most important ones; however, only DHEA and DHEAS
have been investigated as a possible cause of sexual dys-
function. The routine evaluation of DHEA and DHEAS has
not been recommended in assessment of erectile function;
as for what concerns PE, there are scanty evidences
regarding the hormonal involvement in its pathogenesis.
Cortisol is undoubtedly the most known adrenal hor-
mone: its role on metabolism has been thoroughly inves-
tigated, although evidence on its role on sexual dysfunction
is still inconclusive. Stress management is involved in the
pathogenesis of ED [57, 58]: considering the involvement
of cortisol in coping with stress, we suppose that it might
be interesting to evaluate cortisol levels in patients with
PE, even if literature does not provide evidence in this
regard.
Leptin
Leptin, a hormone identified in 1994 and traditionally
associated with satiety and energy expenditure, has been
extensively studied in the last decades in order to identify
its roles on other physiological processes. Leptin is
involved in the regulation of different elements of the
hypothalamic–pituitary–gonadal axis [59, 60], and its
production might also occur autonomously in human
spermatozoa [61]: based on these assumptions, a role for
leptin in premature ejaculation has been postulated and
studied [62, 63]. Elevated serum leptin seems to be sig-
nificantly associated with PE: however, these studies have
been led on a small scale, and the authors themselves
suggest that more studies are necessary in order to consider
leptin a marker or a diagnostic tool for PE.
Conclusions
Premature ejaculation is the most common male sexual
dysfunction, and yet its pathophysiology remains not
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completely understood [64], though chronic prostatitis [65–
67], lack of privacy [68], and psychorelational/psycho-
sexual issues [69] are considered important causes of PE.
PE significantly affects the sexual life of the couple [13,
70], and has recently been identified as a frequent cause of
relationship breakups [71]. Among the known secondary
causes of PE, hormonal alterations might play a pivotal
role; however, hormones are also frequently involved in
other sexual disorders, therefore complicating the diagnosis
(Fig. 1). Hyperthyroidism has been considered a cause of
PE, and its treatment has been found effective in delaying
ejaculation; low levels of PRL have been found in patients
suffering from PE, although hypoprolactinemia might be a
marker of perturbations in the serotonin pathway. There
seems to be still little evidence in regards to the involve-
ment of other hormones in the pathogenesis of PE. Hence,
we suggest the evaluation of testosterone, estradiol, PRL,
leptin, adrenal hormones, and thyroid functioning only
when significant symptoms suggesting the suspect of
underlying diseases are observed. It should be clear that PE
is often associated with endocrine diseases, requiring
adequate investigation and follow-up by a trained special-
ist: the endocrinologist should be a reference during dif-
ferential diagnosis of PE.
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